Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1534077 | 0.74 | XDH (0.55) | MAOBXDHMAPTTDP1L3MBTL1 | |
| SCHEMBL1534113 | 0.70 | XDH (0.48) | MAOBXDHMAPTTDP1L3MBTL1 | |
| SCHEMBL5027005 | 0.69 | BRD4 (0.46) | MAOBXDHMAPK1 | |
| SCHEMBL21884506 | 0.68 | XDH (0.47) | MAOBXDHMAPTTDP1L3MBTL1 | |
| SCHEMBL15831939 | 0.68 | MAOB (0.56) | MAOBXDHMAPTMAPK1TDP1 | |
| SCHEMBL8874712 | 0.68 | SGMS2 (0.52) | MAOBMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL10822615 | 0.68 | MAOB (0.59) | MAOBXDHMAPTL3MBTL1 | |
| SCHEMBL27386521 | 0.67 | SCN2A (0.45) | HTT | |
| SCHEMBL6555869 | 0.67 | MAOB (0.46) | GRM5MAOB | |
| SCHEMBL448079 | 0.67 | MAOB (0.57) | MAOBXDHMAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390357-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-05 | — | — | US | disclosed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062778-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | SERPINC1, TFPI, F2 | GRM5 2870/4885MAOB 743/4885XDH 292/4885 |
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | GRM5 1584/4885MAOB 815/4885XDH 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.